Pfizer Ltd.

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has demonstrated a marked improvement in its financial performance for the quarter ended June 2026. The company’s financial trend has shifted from flat to positive, driven by record-breaking revenue and profitability metrics, signalling a potential turnaround despite a challenging broader market environment.

Pfizer Ltd. reported a net profit of ₹204.47 crores for Q1 FY27 (quarter ended June 2026), marking a sequential increase of 2.33% from ₹199.82 crores in Q4 FY26 and a year-on-year growth of 6.63% from ₹191.75 crores in Q1 FY26. The pharmaceutical major, with a market capitalisation of ₹21,584 crores, demonstrated resilient operational performance with its highest-ever quarterly revenue and operating profit margins, though investors remain cautious as the stock trades 19.95% below its 52-week high of ₹5,878.55.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 July 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a modest day gain of 0.35%, the stock’s recent downgrade from Hold to Sell by MarketsMOJO underscores growing caution among analysts as technical indicators reveal a transition from bearish to mildly bearish trends.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This change is underscored by deteriorating technical indicators including MACD, moving averages, and Bollinger Bands, signalling increased selling pressure and subdued investor sentiment as the stock price declined by 2.64% on 20 Jul 2026.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. Despite a recent upgrade from Hold to Sell in its Mojo Grade, the stock’s price action and technical parameters reveal nuanced trends that investors should carefully analyse amid broader market dynamics.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 Dec 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 05 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions and raises questions about the stock's price attractiveness relative to its historical averages and peer group. Despite robust returns over the past decade, recent performance and valuation metrics suggest a cautious stance for investors.

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, witnessed its stock price decline to a fresh 52-week low of Rs.4392.55 on 29 June 2026, marking a significant milestone in its recent market performance. This decline reflects ongoing pressures on the stock, which has underperformed both its sector and broader market indices over the past year.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Despite a broadly resilient market, Pfizer Ltd. has slipped to a fresh 52-week low of Rs 4,440 on 4 Jun 2026, marking a 22.54% decline over the past year and underperforming the Sensex by over 14 percentage points.

For the fifth straight session, Pfizer Ltd. closed lower, breaching its 52-week low at Rs 4,450 on 3 Jun 2026, marking a significant decline amid broader market weakness.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This change is underscored by deteriorating technical indicators including MACD, Bollinger Bands, and moving averages, signalling increased selling pressure and subdued price momentum as the stock struggles to maintain its recent levels.